1 / 31

Post Operative Nausea & Vomiting

Post Operative Nausea & Vomiting. Nicole Weiss MD September 22, 2010. Objectives. Importance PONV Risk Factors Review of anti-emetics and strategies aimed at reducing PONV Risk based treatment Rescue Therapy Tulane University Pharmacy. The Patient.

lorand
Download Presentation

Post Operative Nausea & Vomiting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Post Operative Nausea & Vomiting Nicole Weiss MD September 22, 2010

  2. Objectives • Importance PONV • Risk Factors • Review of anti-emetics and strategies aimed at reducing PONV • Risk based treatment • Rescue Therapy • Tulane University Pharmacy

  3. The Patient • 41 y/o female with a h/o of PONV scheduled for an outpatient laparoscopic cholecystectomy • Motion sickness • Non-smoker

  4. PONV: Importance? • High Level of patient concern (second to pain) • -willingness to pay $56-$100 • Major cause of unanticipated hospital admissions • Rare complications: pulmonary aspiration, incisional disruption

  5. Physiology • Vomiting Center • Located in the Medulla • Tickling the back of the Throat • Gastric Distension • Vestibular Stimulation (Etoh) • Cerebral Cortex • Chemoreceptor trigger zone • Outside of the BBB communicates with the vomiting center • Blood Borne Drugs or Hormones • Neurotransmitters involved: • Dopamine, 5-HT, Substance P, Ach

  6. Apfel. Miller's Anesthesia.

  7. Strategies for Minimizing PONV • Identify high risk patients -25-30% incidence of PONV -0.18% intractable PONV • Avoid emetogenic stimuli • Multimodal antiemetic therapy

  8. Risk FactorsPatient, Procedure, Anesthesia • History of previous PONV • History of motion sickness • History of migraines • Female gender post puberty • Childhood after infancy and young adulthood • Nonsmoker • The type of surgery: laparoscopic, middle ear, ophthalmologic, craniotomy • Increasing duration of surgery • Dehydration • Pain • Use of volatile anesthetics, opioids, nitrous oxide or neostigmine “Up to 70% incidence of PONV in “high risk” patients (Kim)

  9. Apfel’s Simplified Risk (Adults) • 1,2,3 or 4 risk factors-->10, 20,60,80% • Female • H/o of PONV or motion sickness • Non smoking • Postoperative IV opiods Apfel, et al. NEJM. 2004.

  10. Drugs associated with PONV • Nitrous oxide • Volatile agents • Etomidate • Neostigmine (high doses) • Excessive opiods

  11. Comparison of Agents Apfel, et al. 2002.

  12. Protective Anesthesia • Hydration • Regional Anesthesia • TIVA • Utilizing propofol as effective as ondansetron • Dose response relationship for propofol • Oxygen • Acupuncture

  13. Antiemetics • Antagonists of 5-HT3 • Antagonists of D2 • Antagonists of H1 • Antagonists of M Receptors • Antagonists of Neurokinin-1 • Corticosteroids

  14. Dopaminergic Agents • Haloperidol • Similar efficacy to ondansetron • Not approved for IV use secondary to cardiac arrhythmias • Droperidol • Effective • Short half life-3 hours • Increased sedation • FDA black label

  15. Clinically Relevant? • Study comparing ondansetron and droperidol QT prolongation Charbit B, et al. Anesthesiology. 2005.

  16. Dopamine Antagonists • Metoclopramide • Prokinetic effects • Studies show 10mg dose no more effective than a placebo • Higher doses (50mg) may be effective • Dyskinetic and extrapyramidal side effects

  17. Other Drugs NOT Included in this Talk • Metoclopramide • Ranitidine • Sodium citrate • Omeprazole • GERD and aspiration precautions are different from PONV

  18. 5HT-3 Antagonists • Ondansetron, granisetron & dolasetron • Work at the chemoreceptor trigger zone & at vagal afferents in the GI tract • Anti-vomiting better than anti-nausea • All three equal in efficacy, few side effects • Four hour half-life, but genetic of polymorphisms of p450 can lead to ultra short metabolism • Palonosetron (Aloxi) • RCT demonstrated efficacy • Approved for PONV in 2008 • Duration of up to 72 hours

  19. Anticholinergics • Scopolamine patch showed to be equally effective to ondansetron • Side effects include: • Dry mouth • Visual disturbances • Dizziness • Agitation

  20. Corticosteroids • Dexamethasone • Meta-analysis shows 8-10mg effective • No reports of dexamethasone-related side effects in small doses • Slow onset of action, better efficacy if given in the beginning of a case

  21. Antihistamines • Dimenhydrinate (Dramamine) & Diphenhydramine • Anticholinergic Properties • Side effects: • Sedation • Dry Mouth • Blurred vision • Urinary Retention • Prolonged recovery from anesthesia • Vascular necrosis (promethazine)

  22. Neurokinin-1 Antagonists (Substance P Receptors) • Work on the final common pathway from the emetic center • Aprepitant (Emend) • Recent studies indicate more effective than ondansetron in preventing emesis, similar efficacy in preventing nausea • Patent expiration 2011-2015 • Casopitant & Rolapitant

  23. Combinations versus single drugs • Multiple RCT compare a combination of antiemetics versus a single agent • Improved outcomes with combinations of anti-emetics (except for studies with metoclopramide)

  24. IMPACT International Multicenter Protocol to Assess Antiemetic Combinations, 2004 • Large multicenter RCT • 5,199 high risk patients • Six Variables: 2x2x2x2x2x2 (64 groups) • Ondansetron • Dexamethasone • Droperidol • Air (versus NO) • Propofol (versus inhaled agents), • Remifentanil (versus fentanyl) • Primary Outcome- PONV in 1st 24 hours • Relative risk of combined antiemetics equal to multiplying the relative risk of each single agent together Apfel, C, et al. IMPACT. Anaesthetist. 2005.

  25. Algorithms for the prevention of PONV • Risk adapted algorithms can reduce PONV in select patient populations • None have proved to be universally applicable

  26. Guidelines for Antiemetic Therapy • Patient Factors • Female • H/o of PONV or motion sickness • Non-smoker • Use of opiods • Surgical Factors • Laparoscopy • Laparotomy • Craniotomy • Strabismus • ENT 2-4 Factors 1. Droperidol +5HT-3 Antag 2. Decadron+5HT-3 Antag. 3. Droperidol+Decadron >4 Factors Combination of antiemetics + TIVA with propofol 1-2 Factors 5HT-3 Antag. Decadron Scopolamine Droperidol Evidence Based Anesthesia

  27. Rescue Therapy • Lack of data • Mechanical Factors: • Secretions, gastric distension, opiates • Choose a different drug class in the first six hours • 5HT-3 Antagonists • Non-sedating • Better anti-vomiting than anti nausea • Not dose responsive • Not indicated if failed ondansetron prophylaxis • Droperiol • Dexamethasone

  28. Tulane Pharmacy Costs • Wholesale Price • Markup 5x wholesale price • Submitted to Insurance Company • Government Reimbursement for Operative Antiemetic Drugs • Facility Surgery Fee

  29. Ondansetron $0.78 per dose • Droperidol $4.08 • Dimenhydrinate$0.04 Courtesy of Bob Self, Tulane Pharmacy Director

  30. What does this mean? • High risk patients ALWAYS warrant aggressive prophylaxis • Ondansetron • 50 patients a day, 260 days a year…costs Tulane: $57,000 per year • Puts patients at risk for side effects • Only 0.18% patients experience severe PONV requiring hospitalization…almost all can be identified by risk factors

  31. References • Costanzo, Linda. Physiology. 4th Ed. Lippincott Williams & Wilkins: Philadelphia, 2007. • Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analog 2006;102:1884-98. • Gan, T.J. Effective Management of PONV and Pain in Ambulatory Settings. • Glidden, Randall. NMS Clinical Manuals. Lippincott Williams & Wilkins: Philadelphia, 2003. • Habib, Ashraf. What Is the Best Strategy to Prevent Postoperative Nausea and Vomiting? Evidence-Based Practice of Anesthesiology. 2nd edition. Sunders Elsevier. 269-275. • Kranke P. Algorithms for the prevention of postoperative nausea and vomiting: an efficacy and efficiency simulation. European Journal of Anaesthesiology 2007, 24,10:856-867. • Kim, Eun Jin. Combination of Antiemetics for the Prevention of Postoperative Nausea and Vomiting in High Risk Patients. J Korean Med Sci 2007; 22:878-82. • Apfel, CC. A Factorial Trial Six Interventions for the prevention of postoperative nausea and vomiting. Anaesthesist. 54 (3). Mar 2005. 201-9. • Apfel CC., Kranke P, Katz MH, et al: Volatile Anesthetics may be the main cause of early, but not delayed postoperative vomiting: A randomized controlled trial of factorial design. Br J of Anesthesia. 88: 659-668, 2002. • Apfel, CC, Korttila K, Abdallah M, et al.: A factorial Trial of Six interventions for postoperative nausea and vomiting. New England Journal of Medicine. 2004; 350, 2441-2451. • Miller, R, et al. Miller’s Anesthesia. 7th ed. Churchill Livingstone: 2009. • Kovac A. A randomized, double-blind controlled trial of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesthesiology Analogue. 107 (2): 439-44. • Charbit B, et al.. AnesthesioDroperidol and ondansetron-induced QT interval prologation: a clinical drug interaction studylogy. Aug 2008; 109 (2): 206-12.

More Related